What options for therapy for severe asthma are available for the non-eosinophilic phenotype?
In the new era of once a day inhalers for Asthma and COPD, there is critical need to determine whether delivery of drugs to the lung at night or day have different therapeutic effects and/or side effect profile.
Asthma-COPD overlap syndrome is common and associated with increased morbidity and greater healthcare costs. However, ACOS patients are usually excluded from studies of either disease. There is a compelling need for research in order to define objective diagnostic criteria for ACOS.
More evidence-based, scientifically proven interventions to ensure that scientific information is translated into clinical and public health practices and programs to reduce the burden of asthma and allergies on individuals, families and society
A large gap in healthcare is nonadherence to proven effective treatments. One important area for reducing morbidity, mortality and cost for patients with chronic diseases that require frequent home, non-healthcare assisted, administration of treatment is the promotion of adherence to treatment recommendations.
Need to develop and integrate biomarkers of asthma into phenotype/endotype-driven asthma management algorithms
There are lots of exercise regimens for COPD, but none that I can find for asthmatics
Study patient-provider communication of asthma self-management requirements to see where gaps in communication may contribute to suboptimal self-management decisions. Examine patients’ decision-making in the home management of asymptomatic and acute. Compare different approaches to the delivery of asthma self-management education and best practices for supporting the patient as they gain competency in this area.
Integrate real time data acquired from or through mobile health care applications (apps) and devices into asthma and allergy management.
As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Given the development of specific biologic therapy for asthma, what are the biomarkers and predictors of response that will allow clinicians to choose the best therapeutic combination of medications (biologic and otherwise) ...more »
Approach, diagnostics and management of asthma-COPD overlap syndrome.
NIH has a major initiative in Precision Medicine, including whole genome sequencing. In contrast to cancer, mutations with large clinical effects are expected to be uncommon in most non-malignant chronic diseases, such as asthma and COPD. Other data types such as gene expression, biomarkers, and micro RNAs must be combined with clinical and imaging phenotyping to advance Precision medicine in non-malignant lung diseases. ...more »